ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,572.85
      0.10%
      US Tech 100
      19,966.40
      0.37%
      Dow Jones
      39,344.79
      -0.08%
      Brent Oil
      85.135
      -0.33%
      Bitcoin
      57,422.82
      1.26%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vertex Pharmaceuticals Inc (VRTX)

      7. Vertex Pharmaceuticals Inc (VRTX) News

      VRTX

      Vertex Pharmaceuticals (VRTX)

      Vertex Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VRTX
      DateTimeSourceHeadlineSymbolCompany
      04/12/20234:49PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/10/202311:16AMDow Jones NewsVertex Gets Authorization in Canada for Expanded Use of Orkambi in Children with Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
      04/10/202310:25AMPR Newswire (Canada)Vertex annonce l'autorisation de commercialisation par Santé Canada de ORKAMBI(MD) (lumacaftor/ivacaftor) chez les enfants atteints de fibrose kystique âgés de 1 à < 2 ansNASDAQ:VRTXVertex Pharmaceuticals Inc
      04/10/202310:16AMPR Newswire (Canada)Vertex Announces Health Canada Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to <2 YearsNASDAQ:VRTXVertex Pharmaceuticals Inc
      04/10/20238:05AMBusiness WireVertex to Announce First Quarter 2023 Financial Results on May 1NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/06/20234:39PMEdgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/06/20234:37PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/06/20234:35PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/04/20234:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      04/03/20238:00AMBusiness WireVertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
      03/28/20234:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/27/20238:00AMBusiness WireVertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 DiabetesNASDAQ:VRTXVertex Pharmaceuticals Inc
      03/24/202312:01PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/21/20234:21PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/20/20234:27PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/17/20231:07PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/16/20238:00AMBusiness WireVertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/13/20234:17PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/10/20234:17PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:VRTXVertex Pharmaceuticals Inc
      03/09/20238:59AMDow Jones NewsVertex Gets FDA OK for Studies of VX-264 Cell Therapy in Type 1 DiabetesNASDAQ:VRTXVertex Pharmaceuticals Inc
      03/09/20238:00AMBusiness WireVertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 DiabetesNASDAQ:VRTXVertex Pharmaceuticals Inc
      02/28/20235:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/28/20235:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/28/20235:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/28/20235:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/28/20234:44PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/22/20234:54PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/22/20234:51PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/22/20234:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
      02/22/20234:34PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRTXVertex Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:VRTX